CAPTIVATE MRD Cohort: 2-Yr Postrandomization Efficacy and Safety With First-Line Ibrutinib + Venetoclax in CLL

December 11-14, 2021; Atlanta, Georgia
Initial therapy with ibrutinib + venetoclax for 12 cycles resulted in a 2-year DFS rate of 95.3% in patients with undetectable MRD who were subsequently randomized to placebo and 100% in those subsequently randomized to ibrutinib.
Format: Microsoft PowerPoint (.ppt)
File Size: 206 KB
Released: December 21, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Daiichi Sankyo, Inc.
GlaxoSmithKline
Incyte Corporation
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Related Content

Watch a short video that provides an expert review of the evolution in CLL treatment over the past several years, from Clinical Care Options (CCO)

Nicole Lamanna, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: August 15, 2022 Expired: August 14, 2023

In slides from Clinical Care Options (CCO), gain expert insights into the evolution in CLL treatment over the past several years

Nicole Lamanna, MD Released: August 15, 2022

Comentario experto de los datos de la EHA 2022 sobre inhibidores de la QBT para LLC y LCM de Clinical Care Options (CCO)

person default Othman Al-Sawaf, MD Lydia Scarfò, MD Released: August 15, 2022

Expertengespräch über die Daten der EHA 2022 zu BTK-Inhibitoren für CLL und MCL, von Clinical Care Options (CCO)

person default Othman Al-Sawaf, MD Lydia Scarfò, MD Released: August 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings